Long-term pharmacotherapy for obesity and overweight-Reference-Cited by-同舟云学术

Long-term pharmacotherapy for obesity and overweight

Published:2003-10-20 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Padwal Raj S¹,Rucker Diana²,Li Stephanie K³,Curioni Cintia⁴,Lau David CW⁵

Affiliation:

1. University of Alberta Hospital; 2E3.22 WMHSC; Edmonton, AB Canada T6G 2B7

2. University of Alberta; Internal Medicine ; 8440-112 St Edmonton, AB Alberta Canada T6G 2B7

3. University of Alberta ; Internal Medicine (PGY4); 10820-85 Ave Edmonton, AB Canada T6E 2L1

4. Universidade do Estado do Rio de Janeiro; Instituto de Medicina Social; Rua São Francisco Xavier, 524 / 7º andar / bloco D - Maracanã Rio de Janeiro Brazil 20559-900

5. University of Calgary; Department of Medicine; 2501-3330 Hospital Drive NW Calgary Alberta Canada T2N 4N1

Publisher

Wiley

Subject

Pharmacology (medical)

Reference131 articles.

1. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine;Apfelbaum;American Journal of Medicine,1999

2. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension;Bakris;Journal of Hypertension,2002

3. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin;Berne;Diabet Med,2005

4. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study;Broom;International Journal of Clinical Practice,2002

5. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat;Davidson;Journal of the American Medical Association,1999

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post‐bariatric treatment failure;Clinical Obesity;2023-06-26

2. Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon;Journal of Obesity & Metabolic Syndrome;2023-06-23

3. Inhibitory Potential of α-Amylase, α-Glucosidase, and Pancreatic Lipase by a Formulation of Five Plant Extracts: TOTUM-63;International Journal of Molecular Sciences;2023-02-11

4. Gastric Bypass Versus Sleeve Gastrectomy: Comparison of Patient Outcomes, Satisfaction, and Quality of Life in a Single-Center Experience;Journal of Laparoendoscopic & Advanced Surgical Techniques;2023-02-01

5. The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis;Obesity Surgery;2022-07-25